- Home
- CKPT vs FT Comparison
CKPT vs FT Comparison
Compare CKPT & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- FT
- Stock Information
- Founded
- CKPT 2014
- FT 1988
- Country
- CKPT United States
- FT United States
- Employees
- CKPT N/A
- FT N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- FT Trusts Except Educational Religious and Charitable
- Sector
- CKPT Health Care
- FT Finance
- Exchange
- CKPT Nasdaq
- FT Nasdaq
- Market Cap
- CKPT 214.4M
- FT 189.6M
- IPO Year
- CKPT 2017
- FT N/A
- Fundamental
- Price
- CKPT $3.61
- FT $7.28
- Analyst Decision
- CKPT Strong Buy
- FT
- Analyst Count
- CKPT 3
- FT 0
- Target Price
- CKPT $10.33
- FT N/A
- AVG Volume (30 Days)
- CKPT 2.4M
- FT 63.0K
- Earning Date
- CKPT 11-12-2024
- FT 01-01-0001
- Dividend Yield
- CKPT N/A
- FT 7.85%
- EPS Growth
- CKPT N/A
- FT N/A
- EPS
- CKPT N/A
- FT N/A
- Revenue
- CKPT $47,000.00
- FT N/A
- Revenue This Year
- CKPT N/A
- FT N/A
- Revenue Next Year
- CKPT $151,162.55
- FT N/A
- P/E Ratio
- CKPT N/A
- FT N/A
- Revenue Growth
- CKPT N/A
- FT N/A
- 52 Week Low
- CKPT $1.38
- FT $5.97
- 52 Week High
- CKPT $4.50
- FT $7.23
- Technical
- Relative Strength Index (RSI)
- CKPT 41.64
- FT 20.83
- Support Level
- CKPT $2.98
- FT $7.59
- Resistance Level
- CKPT $4.44
- FT $7.78
- Average True Range (ATR)
- CKPT 0.42
- FT 0.12
- MACD
- CKPT -0.10
- FT -0.06
- Stochastic Oscillator
- CKPT 25.66
- FT 8.00
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.